GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibikase Therapeutics Inc (NAS:IKT) » Definitions » Retained Earnings

IKT (Inhibikase Therapeutics) Retained Earnings : $-76.51 Mil (As of Jun. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Inhibikase Therapeutics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Inhibikase Therapeutics's retained earnings for the quarter that ended in Jun. 2024 was $-76.51 Mil.

Inhibikase Therapeutics's quarterly retained earnings declined from Dec. 2023 ($-66.90 Mil) to Mar. 2024 ($-71.55 Mil) and declined from Mar. 2024 ($-71.55 Mil) to Jun. 2024 ($-76.51 Mil).

Inhibikase Therapeutics's annual retained earnings declined from Dec. 2021 ($-29.82 Mil) to Dec. 2022 ($-47.87 Mil) and declined from Dec. 2022 ($-47.87 Mil) to Dec. 2023 ($-66.90 Mil).


Inhibikase Therapeutics Retained Earnings Historical Data

The historical data trend for Inhibikase Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibikase Therapeutics Retained Earnings Chart

Inhibikase Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial -12.18 -15.03 -29.82 -47.87 -66.90

Inhibikase Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -58.13 -62.72 -66.90 -71.55 -76.51

Inhibikase Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Inhibikase Therapeutics  (NAS:IKT) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Inhibikase Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
3350 Riverwood Parkway SE, Suite 1900, Atlanta, GA, USA, 30339
Inhibikase Therapeutics Inc is a clinical-stage pharmaceutical company developing therapeutics for Parkinson's disease and related disorders. Its multi-therapeutic pipeline focuses on neurodegeneration and its program for IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, intends to treat Parkinson's disease inside and outside the brain. The company is performing its Phase I, randomized single ascending dose and multiple ascending dose, study to determine the safety, tolerability and pharmacokinetics of IkT-148009 in older and healthy subjects. It is also advancing a novel drug delivery platform to treat certain forms of cancer at the same time as it is developing novel drugs for the treatment of neurodegenerative disease.
Executives
Paul C Grint director 7757 DOUGHILL COURT, SAN DIEGO CA 92127
Dennis N Berman director 9605 SCRANTON RD, STE 240, SAN DIEGO CA 92121
Roy Lester Freeman director 256 SUMMIT AVE, BROOKLINE MA 02446
Gisele Dion director C/O CYTEK BIOSCIENCES, INC., 46107 LANDING PARKWAY, FREMONT CA 94538
Milton H. Werner director, 10 percent owner, officer: President and CEO 3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339
Joseph Frattaroli officer: Cheif Financial Officer
Elizabeth G. O'farrell director 932 SOUTHWOOD BLVD., INCLINE VILLAGE NV 89451
Daniel Kalman 10 percent owner 3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA GA 30339

Inhibikase Therapeutics Headlines

From GuruFocus